Opendata, web and dolomites

NEUREKA SIGNED

A smart, hybrid neural-computo device for drug discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEUREKA project word cloud

Explore the words cloud of the NEUREKA project. It provides you a very rough idea of what is the project "NEUREKA" about.

replication    pathological    registered    brain    dendritic    incurable    drugs    neurological    hybrid    pluripotent    effect    alzheimer    stem    suffers    synaptic    transmission    excitability    simulate    mediate    drive    physiological    societal    diseases    drug    emerge    innovative    burden    fed    optimize    cell    candidate    dysfunction    proof    neuronal    neural    functions    neurodegeneration    back    exacerbating    deficits    contact    culture    pathology    loop    networks    soma    repeated    branches    complementing    exhibiting    closing    introduces    subcellular    lack    failures    population    nanoelectrodes    levels    economical    standard    shortcoming    circuits    assays    axonal    faithfully    network    compounds    multiple    accuracy    functional    reproducing    replicate    computational    tree    unprecedented    biological    whereby    vitro    molecular    synapses    simulated    shift    cultured    human    quantification    discovery    cellular    akin    candidates    disease    neureka    monitor    locations    models    neurons    ipsc    paradigm   

Project "NEUREKA" data sheet

The following table provides information about the project.

Coordinator
IDRYMA TECHNOLOGIAS KAI EREVNAS 

Organization address
address: N PLASTIRA STR 100
city: IRAKLEIO
postcode: 70013
website: www.forth.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 2˙776˙705 €
 EC max contribution 2˙776˙704 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2023-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) coordinator 753˙250.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 756˙452.00
3    MAXWELL BIOSYSTEMS AG CH (ZURICH) participant 466˙562.00
4    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 465˙440.00
5    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 335˙000.00

Map

 Project objective

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the functional assessment of candidate compounds at multiple levels: from synapses to neuronal circuits. NEUREKA introduces an innovative, hybrid technology, whereby detailed, computational neuronal networks simulate dysfunction and drive cultured neurons to replicate in-brain disease conditions. Nanoelectrodes mediate the transmission between simulated and biological neurons. Akin to real synapses, nanoelectrodes contact cultured neurons at subcellular locations across the dendritic tree, soma and axonal branches, allowing to control and monitor neural activity with unprecedented accuracy. Biological neuronal responses registered by nanoelectrodes are fed back to simulated neurons, closing the loop and enabling control of activity states across the hybrid population. Complementing molecular deficits already present in culture models of a disease, computational models enable replication of both molecular and physiological deficits of neurodegeneration in vitro. Cultured neurons are driven towards pathological excitability states where deficits emerge, so as to optimize quantification of the impact of drugs, going well beyond standard cellular assays. A proof-of-concept will be provided for Alzheimer’s disease, using human induced pluripotent stem cell (iPSC)-derived neurons exhibiting the pathology. NEUREKA will be used to demonstrate the effect of drug candidates across synaptic, neuronal and network functions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUREKA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUREKA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

cFLOW (2019)

Coherent ultraFast Long Wave infrared communications

Read More  

LABELFREE (2019)

LABEL FREE IMAGING WITH PHI-SCAT

Read More  

BioCombs4Nanofibers (2019)

Antiadhesive Bionic Combs for Handling of Nanofibers

Read More  
lastchecktime (2020-10-31 7:44:10) correctly updated